1603P - Serum plasma leptin levels and life expectancy in cancer patients with terminal illness

Date 01 October 2012
Event ESMO Congress 2012
Session Poster presentation III
Topics Palliative Care
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Chiara Spoto
Authors C. Spoto1, M. Iuliani1, A. Zoccoli1, F. Pantano1, F.M. Guida1, S. Intagliata1, V. Limetti1, B. Vincenzi2, G. Tonini1, D. Santini1
  • 1Medical Oncology, university campus bio-medico, 00128 - rome/IT
  • 2university campus bio-medico, 00128 - rome/IT

Abstract

Introduction

Excess body fat (assessed by Body Mass Index, BMI) is an established risk factor in various cancers and high BMI is directly associated with elevated levels of leptin. Leptin, in addition to its neuroendocrine function involved in the regulation of appetite, can act as a mitogen and an angiogenic factor and it seems also associated with cancer cachexia and chronic inflammation. However, data on the association between leptin levels and cancer progression are contradictory and not definitive. The objective of the present prospective study was to investigate the relationship between leptin and life expectancy in advanced cancer patients, regardless of the primitive tumor.

Methods

We assessed Palliative Prognostic (PaP)-Score in cancer patients from the Medical Oncology Unit at CampusBio-MedicoHospital in Rome. PaP-score ranked patients into three groups with a different 30-day survival probability (A = 82%; B = 52.7%; C = 9.6% respectively). We enrolled 20 patients for each PaP-Score subgroup. For each patient, leptin serum levels were measured by ELISA (Enzyme-Linked ImmunoSorbent Assay) using commercially available kit (R&D System). Statistical analysis was performed using Mann-Whitney U-test.

Results

The mean leptin serum concentration in PaP-Score C subgroup was significantly higher compared to PaP-Score A patients subgroup (P = 0.046) with an increase in mean leptin levels of 115%. No statistically significant difference was observed in mean leptin serum levels beetwen PaP-Score B vs PaP-Score A patients (increase of 7%).

Conclusions

This study showed for the first time a correlation between leptin serum levels and life expectancy in end-stage cancer patients according to PaP-Score. Further studies in larger populations are warranted to clarify the weight of these preliminary results.

Disclosure

All authors have declared no conflicts of interest.